Zimmer Biomet Holdings Inc(NYSE:ZBH) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $1.93B. Analysts estimated a revenue of $1.90B. Earnings per share were $2.02. Analysts had estimated an EPS of $1.97.
In a different note, Guggenheim Securities said it Initiates Coverage on Zimmer Biomet Holdings Inc, according to a research note issued on Jun 9, 2016. The shares have been rated ‘Neutral’ by the firm. On May 25, 2016, Argus Research said it Upgrades its rating on Zimmer Biomet Holdings Inc. The shares have been rated ‘Buy’ by the firm. On May 25, 2016, Argus Research said it Upgrades its rating on Zimmer Biomet Holdings Inc. The shares have been rated ‘Buy’ by the firm. On May 2, 2016, Leerink Swann said it Maintains its rating on Zimmer Biomet Holdings Inc. In the research note, the firm Raises the price-target to $124.00 per share. The shares have been rated ‘Outperform’ by the firm.
Zimmer Biomet Holdings Inc (ZBH) made into the market gainers list on Thursdays trading session with the shares advancing 0.37% or 0.48 points. Due to strong positive momentum, the stock ended at $130.91, which is also near the day’s high of $131.08. The stock began the session at $130.62 and the volume stood at 9,69,225 shares. The 52-week high of the shares is $131.57 and the 52 week low is $88.27. The company has a current market capitalization of $26,082 M and it has 19,92,38,890 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 12, 2016, Daniel P Florin (Sr. VP, CFO) sold 15,000 shares at $124.98 per share price.Also, On Jun 16, 2016, Tony W. Collins (VP, Controller and CAO) sold 3,611 shares at $116.43 per share price.On Jun 10, 2016, Daniel E. Williamson (Group President) sold 10,000 shares at $119.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.